Targeted Therapy, Tangible Relief: Elagolix in Deep Infiltrating Endometriosis - A Case Series

Background: Deep infiltrating endometriosis (DIE) is a severe form of endometriosis associated with chronic pelvic pain, dysmenorrhea, dyspareunia, infertility, and significant impairment in quality of life. Available medical therapies often provide symptomatic relief but are limited by side effects and recurrence. Objective: To evaluate the effectiveness of Elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist for symptomatic relief for patients with deep infiltrating endometriosis. Methods: This case series included three patients diagnosed with deep infiltrating endometriosis. Pain severity was assessed using the Visual Analog Scale (VAS) before treatment and after three months of therapy. Results: All three patients demonstrated significant improvement in chronic pelvic pain, dysmenorrhea, dyspareunia, and overall quality of life. The mean VAS score decreased from 8.67 before treatment to 1.83 after three months of Elagolix therapy. Conclusion: Elagolix is an effective and well-tolerated non-surgical treatment option for symptomatic deep infiltrating endometriosis, offering significant reduction in pain and improvement in quality of life.